A Phase I, Dose-escalation Trial Evaluating the Safety and Efficacy of Emulsified Isoflurane in Healthy Human Volunteers

Author:

Huang Han1,Li Rui1,Liu Jin1,Zhang Wensheng1,Liao Tianzhi1,Yi Xiaoqian1

Affiliation:

1. From the Department of Anesthesiology (H.H.), West China Second Hospital, Sichuan University, Chengdu, Sichuan, P. R. China, and Department of Anesthesiology and Translational Neuroscience Center (R.L., J.L., W.Z., X.Y.), and Department of Neurological ICU (T.L.), West China Hospital, Sichuan University, Chengdu, Sichuan, P. R. China.

Abstract

Abstract Background This first-in-human volunteer phase I clinical trial aimed to evaluate the safety, tolerability, and anesthesia efficacy of emulsified isoflurane (EI), an intravenously injectable formulation of isoflurane. Methods Seventy-eight healthy volunteers were recruited in this open-label, single-bolus, dose-escalation, phase I trial and were allocated into 16 cohorts. Each volunteer received a single bolus injection of EI. The dose started with 0.3 mg/kg (for isoflurane) and was planned to end with 64.6 mg/kg. Postdose vital signs, physical examination, laboratory tests, chest radiograph, 12-lead electrocardiogram, and development of any adverse event were closely monitored as safety measurements. Effectiveness in producing sedation/anesthesia was assessed by Modified Observer’s Assessment of Alertness/Sedation and Bispectral Index. Results The dose escalation ended as planned. The most common adverse events associated with EI were injection pain (77 of 78, 98.7%) and transient tachycardia (22 of 78, 25.6%). Only at high doses (≥38.3 mg/kg) did EI cause transient hypotension (5 of 78, 6.4%) or apnea (11 of 78, 14.1%), but all the affected volunteers recovered uneventfully. Fast onset of unconsciousness (typically 40 s after injection) was developed in all volunteers receiving doses of 22.6 mg/kg or greater. Waking-up time and depression in Modified Observer’s Assessment of Alertness/Sedation correlated well with EI dose. None of the postdose tests revealed any abnormal result. Conclusions EI is safe for intravenous injection in human volunteers in the dose range of 0.3 to 64.6 mg/kg. At doses of 22.6 mg/kg or higher, EI produced rapid onset of unconsciousness in all volunteers followed by fast, predictable, and complete recovery.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Anesthesiology and Pain Medicine

Reference18 articles.

1. Isoflurane: A review.;Anesthesiology,1981

2. New inhaled anesthetics.;Anesthesiology,1994

3. The extent of metabolism of inhaled anesthetics in humans.;Anesthesiology,1986

4. Intravenous injection of liquid halothane.;Anesth Analg,1989

5. Acute pulmonary edema after intravenous liquid halothane in dogs.;Anesth Analg,1992

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3